Showing 6181-6190 of 8782 results for "".
- NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indicationshttps://practicaldermatology.com/news/20140102-nexeption_llc_forms_new_company_alexar_therapeutics_inc_to_develop_novel_lxr_agonist_portfolio_for_dermatologic_indications/2459383/NeXeption, LLC, a biopharmaceutical management company that brings together product opportunities, management expertise and funding to reach compelling partnership milestones, has secured $21.5 million in Series A financing to form Alexar Therapeutic
- Cutera Appoints Scott Ashworth as Executive Vice President of Global Saleshttps://practicaldermatology.com/news/20131230-cutera_appoints_scott_ashworth_as_executive_vice_president_of_global_sales/2459385/Scott Ashworth recently joined Cutera as Executive Vice President of Global Sales. He brings twenty-five years of experience in building and leading global sales and marketing teams focused on commercialization of products, establishing distributio
- First Practice in Northwest Adopts ARTAS® Robotic Systemhttps://practicaldermatology.com/news/20131230-first_practice_is_northwest_adopts_artas_robotic_system/2459386/Advanced Hair Restoration of Bellevue, WA has installed the revolutionary ARTAS® Robotic System — the first and only FDA-cleared, physician-controlled, computer-assisted techno
- CSF 2013 Honors Top Resident Presentershttps://practicaldermatology.com/news/20131219-csf_2013_honors_top_resident_presenters/2459388/Nine residents have been recognized for their presentations at Cosmetic Surgery Forum 2013 held earlier this month. From a panel of residents who presented their research on a range of medical and cosmetic dermatology topics, the top
- Cynosure Announces Successful Settlement of Patent Infringement Lawsuitshttps://practicaldermatology.com/news/20131217-cynosure_announces_successful_settlement_of_patent_infringement_lawsuits/2459393/Cynosure, Inc. will receive $10 million plus future royalty payments under a comprehensive settlement agreement with Tria Beauty, Inc. that ends the patent infringement litigation between Tria and Palomar Medical Technologies, which
- Valeant Pharmaceuticals to Acquire Solta Medicalhttps://practicaldermatology.com/news/20131216-valeant_pharmaceuticals_to_acquire_solta_medical/2459394/Valeant Pharmaceuticals International, Inc. announced that it has entered into a definitive agreement to acquire all of the outstanding common stock
- Topical Nitric Oxide Shows Promisehttps://practicaldermatology.com/news/20131212-topical_nitric_oxide_shows_promise/2459395/Novan is kicking off a two-year program to support the pharmaceutical development of Nitric Oxide Advanced Healing (NOAH) technology, including formulation work, nonclinical toxicology, and proof of concept studies in models of deep partial-thickness and full-thickness thermal injuries. The
- LEO Pharma Expands QualityCareTM Patient Support Programhttps://practicaldermatology.com/news/20131126-leo_pharma_expands_qualitycaretm_patient_support_program/2459403/LEO Pharma Inc. has expanded its QualityCareTM Program, a free and confidential patient support service for people affected by psoriasis or actinic keratosis. In addition to live nurse support through the www.qualitycarebyleo.com, the website also allows patients to choose relevant topics of interes
- Valeant Pharmaceuticals Announces Appointment of Dr. Ari Kellen to Executive Management Teamhttps://practicaldermatology.com/news/20131125-valeant_pharmaceuticals_announces_appointment_of_dr_ari_kellen_to_executive_management_team/2459405/Valeant Pharmaceuticals International, Inc. announced that Dr. Ari Kellen has been named to Valeant's Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1,
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov